Cushing Syndrome
📧 Sign up to get email alerts when something new happens for Cushing Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS safety_alert · 2018-07-02Clinical Trial Update: The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases
This clinical trial update highlights the risk of adrenal insufficiency and Cushing syndrome associated with glucocorticoid therapy in peopl…
-
CLINICAL_TRIALS trial_result · 2018-05-08Clinical Trial Update: Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism [Phase 2]
A National Cancer Institute-sponsored Phase 2 trial comparing adrenalectomy versus observation for subclinical hypercortisolism/Cushing synd…
-
CLINICAL_TRIALS trial_result · 2018-03-02Clinical Trial Update: Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism [Phase 4]
A Phase 4 trial evaluating glucocorticoid receptor blockade with mifepristone in patients with mild hypercortisolism has completed and resul…
-
CLINICAL_TRIALS research · 2017-08-16Clinical Trial Update: Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.
This document reports an update to a clinical trial assessing saliva cortisol as a screening test for suspected Cushing's syndrome in pediat…
-
CLINICAL_TRIALS trial_result · 2017-07-25Clinical Trial Update: Alterations of Muscle Secretome Associated With Muscle Atrophy Caused by Glucocorticoids
This completed clinical trial investigates how glucocorticoids alter the muscle secretome and contribute to muscle atrophy in Cushing syndro…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2017-05-10Clinical Trial Update: Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating abiraterone acetate for managing Cushing's syndrome in patients with adrenocortical carcinoma; curr…
-
CLINICAL_TRIALS research · 2017-03-22Clinical Trial Update: Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome [NA]
A completed clinical trial update describing gene expression patterns in adipose tissue from patients with Cushing syndrome.
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study [NA]
This completed trial evaluated the efficacy and safety of posterior retroperitoneoscopic adrenalectomy in adrenal diseases, including pheoch…
-
CLINICAL_TRIALS trial_result · 2016-11-07Clinical Trial Update: A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease [Phase 2]
A Phase 2 study evaluating SOM230 (pasireotide) in patients with pituitary Cushing's disease has completed.
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: Cardiac Steatosis in Cushing's Syndrome [NA]
Clinical trial update focusing on cardiac steatosis in Cushing's syndrome. The current status details are not publicly available.
-
CLINICAL_TRIALS research · 2016-09-26Clinical Trial Update: Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
This clinical trial update investigates whether serum dexamethasone measurement improves the diagnostic accuracy of the overnight dexamethas…
-
CLINICAL_TRIALS research · 2016-09-08Clinical Trial Update: Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors [NA]
Clinical trial update describing adrenal venous sampling in patients with overt or subclinical Cushing syndrome and bilateral adrenal tumors…
-
CLINICAL_TRIALS trial_result · 2016-08-23Clinical Trial Update: Effects of IL-1 Beta on the HPA-axis in Obese Persons [Phase 3]
Phase 3 trial evaluating the effects of interleukin-1 beta on the HPA axis in obese individuals has completed. It relates to metabolic syndr…
-
EMA withdrawal · 2015-06-12EMA Application withdrawn: Corluxin (mifepristone) — FGK Representative Service GmbH
EMA withdrawal of Corluxin (mifepristone) application for Cushing syndrome by FGK Representative Service GmbH.
-
EMA withdrawal · 2015-05-20EMA Application withdrawn: Ketoconazole AID-SCFM (Ketoconazole) — Agenzia Industrie Difesa-Stabilimento Chimico Farmaceutico Militare
EMA withdrawal of the ketoconazole product application for Cushing syndrome by the military pharmaceutical plant.
-
EMA approval · 2014-09-26Ketoconazole HRA recommended for approval in Cushing's syndrome
The EMA recommends granting marketing authorization for ketoconazole hydrochloride (HRA) for the treatment of Cushing's syndrome, based on i…
-
FDA label_change · 2014-07-28FDA Approved: MIFEPRISTONE — Supplemental Application (Corcept Therapeutics Incorporated)
FDA is reviewing a supplemental application for Mifepristone by Corcept Therapeutics. This action typically accompanies changes to labeling …
-
CLINICAL_TRIALS trial_result · 2014-06-20Clinical Trial Update: A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
This entry notes the termination of a Corcept Therapeutics-sponsored clinical trial evaluating recurrent or persistent Cushing's syndrome in…
-
CLINICAL_TRIALS trial_result · 2014-04-02Clinical Trial Update: An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome [Phase 3]
An extension study of CORLUX (mifepristone) for endogenous Cushing's syndrome completed, with results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2013-11-20Clinical Trial Update: Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome [Phase 3]
Phase 3 trial results for mifepristone (CORLUX) in endogenous Cushing's syndrome have been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2013-10-14Clinical Trial Update: Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion [Phase 2]
Phase 2 open-label trial of mifepristone for symptomatic treatment of Cushing's syndrome due to ectopic ACTH secretion; study terminated wit…
-
CLINICAL_TRIALS trial_result · 2013-10-10Clinical Trial Update: Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy [Phase 4]
A Phase 4 randomized trial comparing posterior retroperitoneoscopic adrenalectomy with lateral laparoscopic adrenalectomy for adrenal tumors…
-
CLINICAL_TRIALS trial_result · 2012-05-28Clinical Trial Update: A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome [Phase 3]
Phase 3 trial results for CORLUX (mifepristone) in endogenous Cushing's syndrome, with the study completed and results posted in 2012.
-
FDA approval · 2012-02-17FDA Approved: MIFEPRISTONE — Original Application (Corcept Therapeutics Incorporated)
The FDA approved mifepristone (brand name Korlym) under an original application from Corcept Therapeutics. It is approved for adults with hy…
-
CLINICAL_TRIALS trial_result · 2010-02-15Clinical Trial Update: Cognition, Steroids, and Imaging in Cushings Disease
A completed clinical trial sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases evaluating cognition, steroid e…